Trial Profile
Long Term Follow-Up of Participants Exposed to GSK3377794 (NY-ESO-1c259 T), a Genetically Engineered NY-ESO-1 Specific T Cell Receptor
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Letetresgene autoleucel (Primary)
- Indications Haematological malignancies; Solid tumours; Synovial sarcoma
- Focus Adverse reactions
- Sponsors Adaptimmune; GlaxoSmithKline; GSK
- 22 Sep 2023 This trial has been completed in Sweden, according to European Clinical Trials Database record.
- 21 Jul 2020 Planned number of patients changed from 444 to 250.
- 22 Mar 2020 Planned number of patients changed from 200 to 444.